First data from the FDA's new active surveillance programme highlight how the system might influence drug development programmes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Unleashing the Mini-Sentinel. Nat Rev Drug Discov 11, 255–257 (2012). https://doi.org/10.1038/nrd3713
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3713
This article is cited by
-
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee
Nature Reviews Drug Discovery (2014)